How to access Cotellic (with Zelboraf and optionally Tecentriq) for BRAF V600E/V600K metastatic melanoma from Bahrain: 2026 pathway via medical oncology and combination supply | Reserve Meds
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-20.
Bahrain's adult medical oncology infrastructure is anchored at Salmaniya Medical Complex (the country's main public referral centre), King Hamad University Hospital (KHUH) in Busaiteen, the Bahrain Defence Force (BDF) Royal Medical Services Hospital, and the Bahrain Oncology Center (the dedicated oncology facility under King Hamad University Hospital). Cotellic (cobimetinib) is the Genentech / Roche oral MEK1/2 inhibitor approved by the FDA only in combination with vemurafenib (Zelboraf), with or without atezolizumab (Tecentriq). Bahrain National Health Regulatory Authority (NHRA) registration is verified at intake and the named-patient pathway is available where commercial supply lags. Reserve Meds does not promote one BRAF/MEK combination over another; this page describes the Cotellic combination because that is what the patient or family is asking about.
This page explains how the pathway works in 2026 for a Bahrain-resident adult: who qualifies, where the molecular diagnostics, baseline ophthalmologic exam, baseline echocardiogram, and baseline liver and creatine kinase workup happen, where the prescriptions for Cotellic AND Zelboraf are written and filled together, how the written quote works, what to monitor on therapy, and how the multi-month course settles into a Bahraini family's life with cross-border logistics where they apply.
Ask about Cotellic in Bahrain
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Why Cotellic, and why now
Cotellic is cobimetinib, an oral, highly selective, reversible inhibitor of MEK1 and MEK2. Discovered at Exelixis; developed by Genentech (Roche Group); first FDA approval November 2015. The MAPK pathway logic: BRAF V600E or V600K mutation produces a constitutively active mutant BRAF kinase driving MEK and ERK independently of normal RAS regulation. MEK inhibition downstream of BRAF blocks the paradoxical pathway activation in BRAF wild-type cells (which drives the keratoacanthoma and cutaneous squamous cell carcinoma signal of BRAF monotherapy) and improves overall survival relative to BRAF monotherapy.
Pivotal melanoma approvals:
- coBRIM doublet (Nov 2015; Cotellic 60 mg QD oral, 21 on / 7 off, plus Zelboraf 960 mg BID continuous): median PFS 12.3 versus 7.2 months; median OS 22.3 versus 17.4 months. - IMspire150 triplet (Jul 2020; Cotellic plus Zelboraf plus atezolizumab): median PFS 15.1 versus 10.6 months.
The October 2022 histiocytic neoplasm expansion is a separate use case. Bahrain melanoma practice in 2026 is the focus of this page.
The Cotellic plus Zelboraf doublet is one of three FDA-approved BRAF/MEK doublets (alongside Tafinlar plus Mekinist and Braftovi plus Mektovi). Reserve Meds does not promote one BRAF/MEK combination over another.
What Cotellic is, in plain language
Cotellic is an oral 20 mg tablet. Three tablets (60 mg) once daily for 21 days, then 7 days off, every 28 days. Zelboraf is an oral 240 mg tablet, four tablets (960 mg) twice daily continuously. Both dispensed on a 28-day refill cycle.
Eligibility at a Bahrain medical oncologist's clinic
1. Histologically confirmed unresectable or metastatic cutaneous melanoma. 2. Confirmed BRAF V600E or V600K mutation by NGS, PCR, or IHC with molecular confirmation. 3. Adult patient (18 or older). 4. Staging workup with contrast CT, PET-CT where indicated, and brain MRI. 5. Baseline ophthalmologic examination including slit-lamp, dilated funduscopic exam, and OCT. 6. Baseline echocardiogram with documented LVEF. 7. Baseline LFTs, CK, CBC, comprehensive metabolic panel. 8. Drug interaction screen for CYP3A4 inhibitors and inducers. 9. Photosensitivity counsel for the Gulf climate. 10. Pregnancy and contraception planning.
Bahrain prescribing and supply picture, plainly
In 2026 the Bahrain pathway typically combines an in-country medical oncologist of record at Salmaniya, KHUH, BDF, or Bahrain Oncology Center with a cross-border tumour board review and supply chain in Saudi Arabia or the UAE for complex or triplet cases. The pathway:
1. Diagnosis and BRAF V600 molecular confirmation at the diagnosing centre's pathology lab or sent to a regional reference lab. 2. Multidisciplinary melanoma tumour board review (in-country at Bahrain Oncology Center or cross-border at KFSHRC Riyadh, CCAD). 3. Insurance pre-authorisation for BOTH Cotellic AND Zelboraf in a single combined-rationale submission. NHRA-supervised local insurers and commercial covers (AXA Gulf, NEXtCARE, MSH, Bupa Global, Allianz Care) handle the combination on a case-by-case basis. For Bahraini nationals the public-sector pathway runs through the institutional formulary at Salmaniya or BDF. 4. Named-patient supply through NHRA where commercial supply lags. Reserve Meds supports the documentation pack and Roche regional liaison. 5. Synchronised pharmacy dispense of Cotellic and Zelboraf on a 28-day refill cycle. For cross-border patients the supply is filled in the country of treatment. 6. Ongoing monitoring labs, ophthalmologic surveillance, and echocardiogram per the schedule below.
Cost and quotes
Medicine price: quote on request. You get a written quote for your case before you commit. Monitoring and ancillary costs add to the total.
What to expect on Cotellic, week-by-week
- Photosensitivity: severe and onset early, often within the first 1 to 2 weeks. Gulf climate amplifies the burden. - Retinopathy: serous retinopathy can appear as early as the first cycle. Any new visual symptom prompts urgent ophthalmology review with OCT. - Cardiomyopathy: asymptomatic LVEF decline at the week-4 echo in a meaningful minority. Echo at baseline, week 4, then quarterly.
Other recognised toxicities include diarrhoea, nausea, fever, peripheral oedema, rash, hepatotoxicity, rhabdomyolysis with CK elevation, and hemorrhage.
When Cotellic is the wrong drug
Cotellic plus Zelboraf is not the right answer for BRAF wild-type melanoma, prior clinically significant retinopathy, baseline LVEF below institutional threshold, severe photosensitivity intolerance, concurrent strong CYP3A4 inhibitors or inducers without dose adjustment, severe hepatic impairment, pregnancy, or a patient for whom the treating medical oncologist prefers Tafinlar plus Mekinist or Braftovi plus Mektovi. Reserve Meds does not promote one BRAF/MEK combination over another.
What Reserve Meds does on this case
We are a US-based digital health company. We build the document pack, submit first-review requests to the chosen Bahrain centre (Salmaniya, KHUH, BDF, Bahrain Oncology Center) and the cross-border tumour board reviewer (KFSHRC Riyadh, CCAD) where appropriate, coordinate insurance pre-authorisation for Cotellic AND Zelboraf in parallel, support NHRA named-patient regulatory liaison, set up the first synchronised dispense, and stay with the case through the refill cycle. Clinical decisions remain with your treating medical oncologist and the multidisciplinary melanoma tumour board.
Start your case at reservemeds.com. We respond within one business day in English or Arabic.
Illustrative example cases (composites, not real patients). This content is for general information and does not constitute medical advice. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating medical oncologist.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-20.
Frequently asked questions
How can I get Cotellic in Bahrain if it is not approved or available there?
Reserve Meds coordinates US-sourced Cotellic for patients in Bahrain through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Bahrain and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Cotellic in Bahrain through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Cotellic. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Bahrain, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Cotellic in Bahrain through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Cotellic to a patient in Bahrain?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Cotellic to your treating physician or hospital pharmacy in Bahrain, with appropriate handling for the product.
How long does it take, and what does Cotellic in Bahrain cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Cotellic in Bahrain?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.